Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies

Trial Profile

Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies

Completed
Phase of Trial: Phase 0

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Alzheimer's disease; Tauopathies
  • Focus Diagnostic use
  • Sponsors Molecular NeuroImaging
  • Most Recent Events

    • 15 Dec 2016 Status changed from recruiting to completed.
    • 26 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top